FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2801726413> ?p ?o ?g. }

• W2801726413 endingPage "639.e3" @default.
• W2801726413 startingPage "628" @default.
• W2801726413 abstract "The comparative efficacy of endocrine-based therapies (ETs) for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC) is not well characterized. This network meta-analysis (NMA) synthesized available evidence on progression-free survival (PFS) with first-line ETs for postmenopausal HR+/HER2- mBC.A systematic literature review identified randomized controlled trials of first-line ETs. Pairwise hazard ratios and 95% credible intervals (CrIs) were obtained via a Bayesian NMA model. Subgroup NMAs were conducted among late progressors (disease-free interval ≥12 months from completion of [neo] adjuvant therapy with letrozole or anastrozole at the time of randomization) and de novo patients, defined as patients whose initial BC diagnosis is mBC.Five trials and 5 regimens (ribociclib + an aromatase inhibitor [AI] [LEE + AI], palbociclib + AI [Pal + AI], fulvestrant 250 mg + AI [Ful250 + AI], fulvestrant 500 mg [Ful500], and AI) were selected. LEE + AI, Pal + AI, Ful250 + AI, and Ful500 had significantly longer PFS versus AI (95% CrI upper-bound ≤1). LEE + AI had a 30% and 29%, and Pal + AI had a 31% and 30%, reduced hazard of progression or death versus Ful250 + AI and Ful500 (95% CrI upper-bound ≤1), respectively. The probability of being the most efficacious was 46% for LEE + AI and 54% for Pal + AI. In subgroup analyses among late progressors, LEE + AI had a 4% reduced hazard of progression or death versus Pal + AI but was not statistically significant. In the de novo analysis, Pal + AI and LEE + AI had a 29% and 40% reduced hazard of progression or death versus Ful500, respectively, but were not statistically significant. In both subgroup analyses, all therapies had significantly longer PFS compared with AI.Pal + AI, LEE + AI, Ful250 + AI, or Ful500 as first-line treatment for HR+/HER2- mBC had longer PFS than AI alone. Given the lack of head-to-head clinical trials comparing the efficacy of recently approved first-line ETs for HR+/HER2- mBC, these results have important clinical implications for the treatment of HR+/HER2- mBC in the first-line setting." @default.
• W2801726413 created "2018-05-17" @default.
• W2801726413 creator A5009613880 @default.
• W2801726413 creator A5017286635 @default.
• W2801726413 creator A5022181897 @default.
• W2801726413 creator A5026624461 @default.
• W2801726413 creator A5041751558 @default.
• W2801726413 creator A5049011740 @default.
• W2801726413 creator A5060607239 @default.
• W2801726413 creator A5088601230 @default.
• W2801726413 date "2018-04-01" @default.
• W2801726413 modified "2023-10-14" @default.
• W2801726413 title "Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2– Metastatic Breast Cancer:" @default.
• W2801726413 cites W1271389891 @default.
• W2801726413 cites W1607879668 @default.
• W2801726413 cites W1992332433 @default.
• W2801726413 cites W2031131661 @default.
• W2801726413 cites W2056271161 @default.
• W2801726413 cites W2098270787 @default.
• W2801726413 cites W2125776201 @default.
• W2801726413 cites W2127622911 @default.
• W2801726413 cites W2144790402 @default.
• W2801726413 cites W2159427817 @default.
• W2801726413 cites W2226017319 @default.
• W2801726413 cites W2288763477 @default.
• W2801726413 cites W2311650017 @default.
• W2801726413 cites W2342819511 @default.
• W2801726413 cites W2528767298 @default.
• W2801726413 cites W2542343371 @default.
• W2801726413 cites W2552099557 @default.
• W2801726413 cites W2558360748 @default.
• W2801726413 cites W2591456506 @default.
• W2801726413 cites W2740803632 @default.
• W2801726413 cites W3004533979 @default.
• W2801726413 cites W4294215472 @default.
• W2801726413 cites W633748798 @default.
• W2801726413 doi "https://doi.org/10.1016/j.clinthera.2018.03.004" @default.
• W2801726413 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29609880" @default.
• W2801726413 hasPublicationYear "2018" @default.
• W2801726413 type Work @default.
• W2801726413 sameAs 2801726413 @default.
• W2801726413 citedByCount "7" @default.
• W2801726413 countsByYear W28017264132018 @default.
• W2801726413 countsByYear W28017264132019 @default.
• W2801726413 countsByYear W28017264132020 @default.
• W2801726413 countsByYear W28017264132021 @default.
• W2801726413 crossrefType "journal-article" @default.
• W2801726413 hasAuthorship W2801726413A5009613880 @default.
• W2801726413 hasAuthorship W2801726413A5017286635 @default.
• W2801726413 hasAuthorship W2801726413A5022181897 @default.
• W2801726413 hasAuthorship W2801726413A5026624461 @default.
• W2801726413 hasAuthorship W2801726413A5041751558 @default.
• W2801726413 hasAuthorship W2801726413A5049011740 @default.
• W2801726413 hasAuthorship W2801726413A5060607239 @default.
• W2801726413 hasAuthorship W2801726413A5088601230 @default.
• W2801726413 hasConcept C121608353 @default.
• W2801726413 hasConcept C126322002 @default.
• W2801726413 hasConcept C143998085 @default.
• W2801726413 hasConcept C207103383 @default.
• W2801726413 hasConcept C2775930923 @default.
• W2801726413 hasConcept C2776166826 @default.
• W2801726413 hasConcept C2776215463 @default.
• W2801726413 hasConcept C2776694085 @default.
• W2801726413 hasConcept C2777176818 @default.
• W2801726413 hasConcept C2778504769 @default.
• W2801726413 hasConcept C2778812593 @default.
• W2801726413 hasConcept C2779744173 @default.
• W2801726413 hasConcept C2780482068 @default.
• W2801726413 hasConcept C2780739268 @default.
• W2801726413 hasConcept C44249647 @default.
• W2801726413 hasConcept C530470458 @default.
• W2801726413 hasConcept C71924100 @default.
• W2801726413 hasConceptScore W2801726413C121608353 @default.
• W2801726413 hasConceptScore W2801726413C126322002 @default.
• W2801726413 hasConceptScore W2801726413C143998085 @default.
• W2801726413 hasConceptScore W2801726413C207103383 @default.
• W2801726413 hasConceptScore W2801726413C2775930923 @default.
• W2801726413 hasConceptScore W2801726413C2776166826 @default.
• W2801726413 hasConceptScore W2801726413C2776215463 @default.
• W2801726413 hasConceptScore W2801726413C2776694085 @default.
• W2801726413 hasConceptScore W2801726413C2777176818 @default.
• W2801726413 hasConceptScore W2801726413C2778504769 @default.
• W2801726413 hasConceptScore W2801726413C2778812593 @default.
• W2801726413 hasConceptScore W2801726413C2779744173 @default.
• W2801726413 hasConceptScore W2801726413C2780482068 @default.
• W2801726413 hasConceptScore W2801726413C2780739268 @default.
• W2801726413 hasConceptScore W2801726413C44249647 @default.
• W2801726413 hasConceptScore W2801726413C530470458 @default.
• W2801726413 hasConceptScore W2801726413C71924100 @default.
• W2801726413 hasIssue "4" @default.
• W2801726413 hasLocation W28017264131 @default.
• W2801726413 hasLocation W28017264132 @default.
• W2801726413 hasOpenAccess W2801726413 @default.
• W2801726413 hasPrimaryLocation W28017264131 @default.
• W2801726413 hasRelatedWork W2526218544 @default.
• W2801726413 hasRelatedWork W2613342381 @default.
• W2801726413 hasRelatedWork W2747078758 @default.
• W2801726413 hasRelatedWork W2753431361 @default.

• next